Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
- Authors: Cristina Cristina Chiriaco ; Chiara Donini , Marco Cortese , Stefano Ughetto , Chiara Modica , Ilaria Martinelli , Alessia Proment , Letizia Vitali , Lara Fontani1, Monica Casucci , Paolo Maria Comoglio , Silvia Giordano , Dario Sangiolo , Valeria Leuci , Elisa Vigna
- Publication year: 2022
- Type: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/590685
Abstract
Aberrant activation of the MET receptor in cancer is sustained by genetic alterations or, more frequently, by transcriptional upregulations. A fraction of MET-amplified or mutated tumors are sensible to MET targeting agents, but their responsiveness is typically short-lasting, as secondary resistance eventually occurs. Since in the absence of genetic alterations MET is usually not a tumor driver, MET overexpressing tumors are not/poorly responsive to MET targeted therapies. Consequently, the vast majority of tumors exhibiting MET activation still represent an unmet medical need.